Total Revenue
Zoetis Total Revenue decreased by 6.1% to $2.26B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 2.9%, from $2.20B to $2.26B. Over 4 years (FY 2021 to FY 2025), Total Revenue shows an upward trend with a 5.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates growing market demand or successful price increases, while a decrease suggests market saturation or competitive pressure.
Detailed definition
The total amount of income generated by the sale of goods or services related to the company's primary operations. For a...
Peer comparison
Peer technology firms typically report this as Net Sales or Total Revenue, reflecting the scale of their market reach.
total_revenueHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.95B | $1.99B | $1.97B | $1.99B | $2.05B | $2.00B | $2.04B | $2.00B | $2.18B | $2.15B | $2.21B | $2.19B | $2.36B | $2.39B | $2.32B | $2.20B | $2.46B | $2.40B | $2.41B | $2.26B |
| QoQ Change | — | +2.2% | -1.2% | +1.0% | +3.3% | -2.4% | +1.9% | -2.0% | +9.0% | -1.3% | +2.9% | -1.0% | +7.8% | +1.1% | -3.0% | -5.1% | +11.9% | -2.4% | +0.4% | -6.1% |
| YoY Change | — | — | — | — | +5.3% | +0.6% | +3.7% | +0.7% | +6.2% | +7.4% | +8.5% | +9.5% | +8.3% | +11.0% | +4.7% | +0.4% | +4.2% | +0.5% | +4.0% | +2.9% |
Product Breakdown
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Parasiticides | $600.00M | $530.00M | $519.00M | $562.00M | $673.00M | $564.00M | $542.00M | $586.00M |
| Vaccines | $445.00M | $468.00M | $462.00M | $447.00M | $504.00M | $496.00M | $512.00M | $519.00M |
| Dermatology | $418.00M | $453.00M | $421.00M | $390.00M | $463.00M | $472.00M | $429.00M | $349.00M |
| Anti-infectives | $264.00M | $274.00M | $281.00M | $249.00M | $219.00M | $284.00M | $284.00M | $241.00M |
| Pain and sedation | $221.00M | $219.00M | $217.00M | $210.00M | $217.00M | $204.00M | $209.00M | $203.00M |
| Other pharmaceutical | $153.00M | $169.00M | $180.00M | $159.00M | $172.00M | $178.00M | $188.00M | $158.00M |
| Animal health diagnostics | $103.00M | $101.00M | $100.00M | $103.00M | $110.00M | $110.00M | $111.00M | $117.00M |
| Other Non Pharmaceuticals | $65.00M | $62.00M | $65.00M | $66.00M | $63.00M | $64.00M | $70.00M | $66.00M |
| Contract manufacturing & human health | — | — | $21.00M | $29.00M | $34.00M | $23.00M | $30.00M | $23.00M |
| Medicated feed additives | $74.00M | $91.00M | $51.00M | $5.00M | $5.00M | $5.00M | $12.00M | — |
| Total | $2.36B | $2.39B | $2.32B | $2.20B | $2.46B | $2.40B | $2.41B | $2.26B |
Medicated feed additives was previously reported and has since been discontinued or reclassified. Only currently active segments are shown in the chart.
Business Segments
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| International | $1.04B | $1.02B | $1.04B | $1.01B | $1.07B | $1.06B | $1.12B | $1.15B |
| U.S. | $1.31B | $1.35B | $1.26B | $1.18B | $1.36B | $1.32B | $1.24B | $1.09B |
| Total | $2.36B | $2.39B | $2.32B | $2.20B | $2.46B | $2.40B | $2.41B | $2.26B |
Geographic Breakdown
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Total geographical area | $2.34B | $2.37B | $2.30B | $2.19B | $2.43B | $2.38B | $2.36B | $2.24B |
| Other emerging markets | $222.00M | $220.00M | $195.00M | $248.00M | $225.00M | $228.00M | $212.00M | $291.00M |
| Other developed markets | $138.00M | $148.00M | $151.00M | $133.00M | $162.00M | $164.00M | $182.00M | $169.00M |
| Total | $2.36B | $2.39B | $2.32B | $2.20B | $2.46B | $2.40B | $2.41B | $2.26B |
Total Revenue at Other Companies
Frequently Asked Questions
- What is Zoetis's total revenue?
- Zoetis (ZTS) reported total revenue of $2.26B in Q1 2026.
- How has Zoetis's total revenue changed year-over-year?
- Zoetis's total revenue increased by 2.9% year-over-year, from $2.20B to $2.26B.
- What is the long-term trend for Zoetis's total revenue?
- Over 4 years (2021 to 2025), Zoetis's total revenue has grown at a 5.0% compound annual growth rate (CAGR), from $7.78B to $9.47B.
- What does total revenue mean?
- The total amount of money a company brings in from selling its products and services.